<DOC>
	<DOCNO>NCT02793128</DOCNO>
	<brief_summary>The study investigate ability UroGen 's MitoGel™ procedure treat urothelial carcinoma tumor upper urinary tract . If treatment prove effective lead development new treatment approach patient suffer Low Grade Upper Urinary Urothelial Carcinoma ( UTUC ) .</brief_summary>
	<brief_title>The OLYMPUS Study - Optimized DeLivery Mitomycin Primary UTUC Study</brief_title>
	<detailed_description>Trial TC-UT-03 prospective , single-arm trial , design ass efficacy , safety , tolerability treatment MitoGel™ instill upper urinary system patient non-invasive low-grade ( LG ) , UTUC . Upon sign informed consent , patient undergo screen visit eligibility evaluation . Eligible patient treat MitoGel™ weekly total 6 time ; retrograde fashion . Patients demonstrate CR treat MitoGel™ monthly maintenance therapy total 11 instillation first recurrence whichever come first . Five ( 5 ) week ( ± 1 w ) follow last instillation , PDE Visit , safety efficacy assess , take place . During visit , ablative effect MitoGel™ assess visually , upper tract wash urine cytology , remain tumor , biopsy brush biopsy technically feasible . Patient demonstrate CR PDE undergo monthly maintenance instillation MitoGel™ 11 month post PDE . Safety follow-up patient do one month post last instillation end follow-up period FU visit 12 , early . For patient demonstrate Complete Response , extent possible , remain tumor lesion biopsied . The patient shall undergo additional surgical treatment PI decide deem necessary remove remain tumor . An independent Data Monitoring Committee ( DMC ) assign trial . Accumulating safety , tolerability efficacy data monitor periodically DMC accord pre-specified process frequency detail DMC charter .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<criteria>Main 1 . Patient least 18 year age . 2 . Naive recurrent patient LG , noninvasive UTUC pyelocalyceal system . 3 . Patient least one ( 1 ) measurable biopsyconfirmed papillary LG tumor , evaluate visually , ≤ 15 mm . The large lesion exceed 15mm . 4 . Following biopsy patient least one remain lesion diameter 5 mm . 5 . Patient bilateral LG UTUC may enrol least one side meet inclusion criterion trial kidney require treatment ( The kidney treat prior begin study ) . Main 1 . Patient receive BCG treatment UC 6 month prior Visit 1 . 2 . The patient untreated concurrent urothelial cancer location target area ( unless treat screening ) 3 . CIS past urinary tract . 4 . Patient history invasive urothelial carcinoma urinary tract past 5 ( Five ) year . 5 . Patient history high grade papillary urothelial carcinoma urinary tract past 2 ( Two ) year . 6 . Patient actively treat intend treated systemic chemotherapy duration trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>TC-3</keyword>
	<keyword>Mitogel</keyword>
	<keyword>UTUC</keyword>
	<keyword>Ureteral</keyword>
	<keyword>Upper Tract</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Kidney</keyword>
	<keyword>Renal</keyword>
	<keyword>Gel</keyword>
	<keyword>Local</keyword>
	<keyword>Mitomycin C</keyword>
	<keyword>Prolonged Release</keyword>
	<keyword>Slow Release</keyword>
	<keyword>Kidney Sparing</keyword>
	<keyword>T1</keyword>
	<keyword>T0</keyword>
	<keyword>Low Grade</keyword>
</DOC>